9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Estimated reading time: < 1 min

Condition: Cancer

Estimated Enrollment: 22

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Progression fee survival rate,  Response rate according to modified RECIST criteria,  Toxicity (CTCAE version 4), Overall survival

Interventions: Cetuximab (Erbitux),

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: September 2015

Completion Date: September 2015

Last  Posted Date: February 9, 2017

Location: UZ Antwerpen, Antwerpen, Belgium

Website Link: https://ClinicalTrials.gov/show/NCT00996567

Was this article helpful?
Dislike 0